Antiarrhythmics or Ablation for Ventricular Tachycardia 2
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 416 participants.
Also called NCT02830360
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 416 participants
- Sponsor
- Registry
-
NCT02830360
-
- Other papers using this trial's data
- A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
- Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, France
- Registry status
- Completed
Technical summary
Registry record NCT02830360. Randomized; no masking; primary purpose treatment. Start 2016-10 (actual); primary completion 2024-06-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antiarrhythmics or Ablation for Ventricular Tachycardia 2
- Acronym
- VANISH2
- Condition
- Ventricular Tachycardia (VT)
- Intervention (Drug)
- Antiarrythmic Drug Therapy
- Intervention (Procedure)
- Catheter ablation
- Lead sponsor
- John Sapp
- Collaborator
- Heart and Stroke Foundation of Canada
- Collaborator
- Abbott Medical Devices
- Collaborator
- Biosense Webster, Inc.
- Collaborator
- Ottawa Heart Institute Research Corporation
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- Cardiac Arrhythmia Network of Canada
- Collaborator
- Abbott
- Collaborator
- Nova Scotia Health Authority
Record details
- Record id
cardio:ct-nct02830360- Content hash
e9e492edb2e5b66ceb0c4964496149501da2f133522f7d2829d213420169a008